captopril has been researched along with marimastat in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Balkwill, F; Blann, AD; Caine, GJ; Christodoulos, K; Dobbs, N; Ganesan, TS; Gompertz, N; Harris, AL; Jones, PH; Kakkar, AJ; Kumar, S; Talbot, DC; Thavasu, P | 1 |
| Blann, AD; Caine, GJ; Christodoulos, K; Harris, AL; Lip, GY | 1 |
1 trial(s) available for captopril and marimastat
| Article | Year |
|---|---|
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Captopril; Dalteparin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fibrinolytic Agents; Humans; Hydroxamic Acids; Injections, Subcutaneous; Lymphocytes; Male; Middle Aged; Neoplasms; Phytohemagglutinins; Treatment Outcome; Tumor Necrosis Factor-alpha | 2004 |
3 other study(ies) available for captopril and marimastat
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anticoagulants; Captopril; Dalteparin; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; P-Selectin; Platelet Activation; Thromboplastin; Vascular Endothelial Growth Factor A | 2005 |